Heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) is a versatile RNA-binding protein that plays fundamental roles in post-transcriptional gene regulation and has emerged as a critical player in the neurobiology of neurodegenerative diseases. This protein, encoded by the HNRNPA1 gene in humans, is a member of the heterogeneous nuclear ribonucleoprotein (hnRNP) family, a group of abundant nuclear proteins that associate with pre-mRNA and mature mRNA to facilitate various aspects of RNA metabolism [1].[@qingli2012] The protein is ubiquitously expressed in eukaryotic cells, with particularly high levels in [neurons](/entities/neurons) where it fulfills specialized functions in RNA processing, transport, and localization [2].
The significance of hnRNP A1 in human health has become increasingly apparent with the identification of disease-causing mutations in the HNRNPA1 gene that are linked to amyotrophic lateral sclerosis (ALS), inclusion body myopathy with early-onset Paget disease of bone (IBMPFD), and frontotemporal dementia (FTD) [3].[@qingli2012] Additionally, dysregulation of hnRNP A1 is implicated in the pathogenesis of other neurodegenerative disorders including [Alzheimer's disease](/diseases/alzheimers-disease), Huntington's disease, and [Parkinson's disease](/diseases/parkinsons-disease), making it an important focus of contemporary neuroscience research [4].
Heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) is a versatile RNA-binding protein that plays fundamental roles in post-transcriptional gene regulation and has emerged as a critical player in the neurobiology of neurodegenerative diseases. This protein, encoded by the HNRNPA1 gene in humans, is a member of the heterogeneous nuclear ribonucleoprotein (hnRNP) family, a group of abundant nuclear proteins that associate with pre-mRNA and mature mRNA to facilitate various aspects of RNA metabolism [1].[@qingli2012] The protein is ubiquitously expressed in eukaryotic cells, with particularly high levels in [neurons](/entities/neurons) where it fulfills specialized functions in RNA processing, transport, and localization [2].
The significance of hnRNP A1 in human health has become increasingly apparent with the identification of disease-causing mutations in the HNRNPA1 gene that are linked to amyotrophic lateral sclerosis (ALS), inclusion body myopathy with early-onset Paget disease of bone (IBMPFD), and frontotemporal dementia (FTD) [3].[@qingli2012] Additionally, dysregulation of hnRNP A1 is implicated in the pathogenesis of other neurodegenerative disorders including [Alzheimer's disease](/diseases/alzheimers-disease), Huntington's disease, and [Parkinson's disease](/diseases/parkinsons-disease), making it an important focus of contemporary neuroscience research [4].
This comprehensive overview provides detailed information about the structure, normal physiological functions, and disease-related roles of hnRNP A1, highlighting its importance in maintaining neuronal health and the consequences of its dysfunction.
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">hnRNP A1</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Heterogeneous nuclear ribonucleoprotein A1</td></tr>
<tr><td><strong>Gene</strong></td><td>[HNRNPA1](/genes/HNRNPA1)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P09651](https://www.uniprot.org/uniprot/P09651)</td></tr>
<tr><td><strong>PDB IDs</strong></td><td>1L3K, 2LYV, 4YER</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>34 kDa</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Nucleus, cytoplasm, stress granules</td></tr>
<tr><td><strong>Protein Family</strong></td><td>hnRNP family</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">222 edges</a></td>
</tr>
</table>
</div>
Heterogeneous nuclear ribonucleoprotein A1 is a 372-amino acid protein that belongs to the hnRNP A/B family, which includes closely related proteins such as hnRNP A2/B1, hnRNP A3, and hnRNP A1B [5]. These proteins are characterized by their ability to bind RNA through conserved RNA recognition motifs (RRMs) and to participate in diverse aspects of RNA processing and transport. HnRNP A1 was originally identified as a major component of heterogeneous nuclear ribonucleoprotein complexes in the nucleus, where it associates with pre-mRNA molecules as they are transcribed by RNA polymerase II [1].
The protein exhibits a dynamic subcellular distribution, shuttling between the nucleus and cytoplasm in a process regulated by its interactions with nuclear import and export factors [6]. This nucleocytoplasmic shuttling enables hnRNP A1 to participate in multiple cellular processes, including pre-mRNA splicing in the nucleus, mRNA transport to the cytoplasm, and stress response mechanisms that involve the formation of cytoplasmic stress granules [7].
The molecular architecture of hnRNP A1 reflects its multifaceted functions in RNA binding and protein-protein interactions. The protein contains several distinct structural domains that mediate different aspects of its function:
The N-terminal region of hnRNP A1 contains a glycine-rich domain (approximately amino acids 1-106) that is involved in protein-protein interactions [8]. This low-complexity region lacks well-defined secondary structure but serves as a docking site for various interacting partners, including other hnRNP proteins, transcription factors, and components of the splicing machinery. The glycine-rich nature of this domain provides flexibility and allows for interactions with diverse protein partners [9].
The central region of hnRNP A1 contains two highly conserved RNA recognition motifs (RRMs), also known as RNA-binding domains (RBDs) or RRM1 and RRM2 (amino acids 106-249 and 249-330, respectively) [10]. Each RRM consists of approximately 90 amino acids and adopts the classic RRM fold comprising four β-strands and two α-helices arranged in a βαββαβ configuration. The RRM1 domain has higher RNA-binding affinity and specificity, while RRM2 assists in RNA binding and contributes to the protein's ability to recognize specific RNA sequences [11].
The RRM domains of hnRNP A1 bind to single-stranded RNA and single-stranded DNA with a preference for sequences containing UAG, UAA, and UGA motifs, which are commonly found in pre-mRNA intronic regions and play roles in alternative splicing regulation [12]. The binding affinity and specificity of these domains can be modulated by post-translational modifications, including phosphorylation and methylation, which affect protein-RNA interactions [13].
The C-terminal region of hnRNP A1 contains a prion-related domain (PRD) or low-complexity domain (LCD) spanning approximately amino acids 320-372 [14]. This domain is富含甘氨酸 (glycine-rich) and glutamine (glutamine-rich), with sequence characteristics similar to prion proteins and other aggregation-prone proteins involved in neurodegenerative diseases [15]. The PRD is intrinsically disordered under normal physiological conditions but can undergo conformational transitions to form β-sheet-rich structures that drive protein aggregation [16].
The PRD of hnRNP A1 is prone to liquid-liquid phase separation (LLPS) and can form membraneless organelles, including stress granules and nuclear speckles [17]. This property is central to the protein's role in stress response mechanisms but also underlies its pathogenic aggregation in neurodegenerative diseases when mutations or cellular stress promote aberrant protein assembly [18].
In neurons and other cell types, hnRNP A1 plays critical roles in multiple aspects of RNA metabolism and cellular stress response:
HnRNP A1 is a well-characterized regulator of alternative splicing, a process that generates multiple mRNA isoforms from a single gene and greatly expands proteomic diversity [19]. The protein functions as a splicing regulator by binding to specific sequences within pre-mRNA transcripts, typically located in intronic or exonic regions, and influencing the selection of splice sites by the spliceosome machinery [20].
As a member of the heterogeneous nuclear ribonucleoprotein family, hnRNP A1 can both promote and repress splicing depending on the context of its binding site [21]. When bound to intronic silencing elements, hnRNP A1 can recruit repressive complexes that inhibit the use of nearby splice sites, while binding to enhancer elements can promote splice site selection through interactions with activatory proteins [22]. Through these mechanisms, hnRNP A1 regulates the alternative splicing of numerous neuronal transcripts, including those encoding proteins involved in synaptic function, neuronal development, and axonal guidance [23].
In neurons, the subcellular localization of mRNAs is crucial for regulated protein synthesis at specific cellular compartments, including dendritic and axonal processes [24]. HnRNP A1 participates in mRNA transport by binding to specific sequences within target mRNAs and forming ribonucleoprotein complexes that are transported along the cytoskeleton via motor proteins [25].
The protein has been shown to regulate the transport of several neuronal mRNAs, including those encoding β-actin, CaMKIIα, and MAP1B, which are locally translated at synapses and contribute to synaptic plasticity and neuronal connectivity [26]. The ability of hnRNP A1 to shuttle between the nucleus and cytoplasm is essential for this function, as it must load onto mRNAs in the nucleus and remain associated with them during transport to the cytoplasm [27].
Under conditions of cellular stress, including oxidative stress, heat shock, and viral infection, hnRNP A1 accumulates in cytoplasmic stress granules—membraneless organelles that temporarily store translationally arrested mRNAs and associated proteins [28]. Stress granule formation is mediated by the liquid-liquid phase separation properties of hnRNP A1 and other RNA-binding proteins containing low-complexity domains [29].
Stress granules serve as protective cellular responses that sequester mRNAs and proteins during stress, preventing their degradation and allowing for rapid recovery once stress conditions subside [30]. The recruitment of hnRNP A1 to stress granules is dynamic and reversible, with the protein returning to its normal subcellular distribution upon stress resolution [31]. However, chronic or dysregulated stress granule dynamics may contribute to neurodegenerative disease pathogenesis [32].
Beyond its roles in RNA metabolism, hnRNP A1 binds to telomeric DNA and contributes to telomere maintenance [33]. Telomeres are specialized structures at the ends of chromosomes that protect against degradation and prevent inappropriate DNA repair responses. HnRNP A1 binds to single-stranded telomeric repeats (TTAGGG repeats) and may participate in telomere length regulation and protection [34]. This function links hnRNP A1 to cellular aging and replicative senescence [35].
HnRNP A1 modulates translation initiation and elongation through multiple mechanisms [36]. The protein can bind to the 5' and 3' untranslated regions (UTRs) of specific mRNAs and influence translation efficiency by affecting ribosome recruitment, initiation complex formation, and translational elongation [37]. In some contexts, hnRNP A1 acts as a translational repressor, while in others it promotes translation, depending on the specific mRNA targets and cellular conditions [38].
Dysregulation and mutation of hnRNP A1 have been strongly implicated in the pathogenesis of several neurodegenerative disorders. The protein's tendency to form aggregates, combined with its essential functions in RNA metabolism, makes it particularly vulnerable to pathogenic disruption:
Amyotrophic lateral sclerosis is a progressive neurodegenerative disease characterized by the selective loss of upper and lower motor neurons [39]. Significant evidence links hnRNP A1 to ALS pathogenesis. Dominant mutations in HNRNPA1 were identified in patients with familial ALS and ALS-FTD (frontotemporal dementia) spectrum disorders [40]. These mutations, including p.D262V, p.G294V, and p.P335L, affect the prion-related domain and promote aberrant protein aggregation [41].
The disease-causing mutations in hnRNP A1 enhance the protein's propensity for phase separation and aggregation, leading to the formation of cytoplasmic inclusions that sequester normal hnRNP A1 and other RNA-binding proteins [42]. These aggregates may disrupt normal RNA metabolism, stress granule dynamics, and proteostasis in motor neurons, ultimately contributing to neuronal dysfunction and death [43].
Mutations in HNRNPA1 were first described in association with inclusion body myopathy with early-onset Paget disease of bone (IBMPFD), a multisystem disorder characterized by muscle weakness, bone abnormalities, and in some cases, neurodegeneration [44]. The identified mutations affect the conserved prion-related domain and promote protein aggregation in muscle fibers and neuronal cells [45].
Frontotemporal dementia encompasses a group of neurodegenerative disorders characterized by progressive degeneration of the frontal and temporal lobes of the brain [46]. The overlap between FTD and ALS in terms of shared genetic and pathological features has led to increased investigation of RNA-binding proteins like hnRNP A1 in FTD pathogenesis [47]. [TDP-43](/proteins/tdp-43) proteinopathy, the hallmark pathological feature of most FTD and ALS cases, involves the aggregation of [TDP-43](/mechanisms/tdp-43-proteinopathy) (encoded by the TARDBP gene), and hnRNP A1 is frequently sequestered in these aggregates [48].
In Alzheimer's disease, the most common cause of dementia, hnRNP A1 dysregulation has been documented in affected brain regions [49]. The protein exhibits altered expression, localization, and post-translational modification in Alzheimer's disease brains, and it may contribute to the dysfunction of RNA metabolism that characterizes the disease [50]. Additionally, hnRNP A1 has been shown to interact with proteins involved in Alzheimer's disease pathogenesis, including [tau](/proteins/tau) and amyloid-β precursor protein [51].
Huntington's disease is caused by CAG repeat expansion in the [huntingtin](/proteins/huntingtin) (HTT) gene, leading to mutant huntingtin protein with expanded polyglutamine tracts [52]. HnRNP A1 interacts with mutant huntingtin and is recruited to inclusions in affected neurons [53]. The sequestration of hnRNP A1 in huntingtin aggregates may disrupt its normal functions in RNA splicing and transport, contributing to the widespread RNA processing deficits observed in Huntington's disease [54].
Emerging evidence suggests that hnRNP A1 may play a role in Parkinson's disease pathogenesis [55]. The protein has been implicated in the regulation of [α-synuclein](/proteins/alpha-synuclein) expression and the formation of Lewy bodies, the characteristic protein inclusions found in Parkinson's disease brains [56]. Additionally, hnRNP A1 is recruited to stress granules in cellular models of Parkinson's disease, and this dysregulation may contribute to neuronal vulnerability [57].
HnRNP A1 interacts with numerous proteins to fulfill its diverse cellular functions:
TAR DNA-binding protein 43 (TDP-43) is a closely related RNA-binding protein that shares functional and pathological similarities with hnRNP A1 [58]. Both proteins contain N-terminal domains, RRMs, and C-terminal prion-related domains, and they participate in overlapping aspects of RNA metabolism [59]. In ALS and FTD, TDP-43 and hnRNP A1 are frequently co-aggregated in cytoplasmic inclusions, suggesting shared pathogenic mechanisms [60].
HnRNP A1 interacts with other members of the hnRNP family, including hnRNP A2/B1, hnRNP A3, hnRNP C, and hnRNP K, to form ribonucleoprotein complexes that regulate RNA processing [61]. These interactions are important for the cooperative assembly of hnRNP particles on pre-mRNA transcripts [62].
The protein interacts with components of the spliceosome, including U1-70K, U2AF, and various serine/arginine-rich (SR) proteins, to regulate alternative splicing decisions [63]. These interactions are mediated in part through the glycine-rich domain of hnRNP A1 [64].
For mRNA transport function, hnRNP A1 associates with motor proteins such as kinesin and dynein that mediate intracellular movement along microtubules [65]. These interactions facilitate the transport of mRNA-protein complexes to specific subcellular locations in neuronal processes [66].
The association between HNRNPA1 mutations and neurodegenerative diseases has important clinical implications:
Identification of pathogenic HNRNPA1 mutations enables genetic testing and counseling for at-risk individuals in familial cases of ALS, FTD, and IBMPFD [67]. The availability of genetic testing allows for early diagnosis and potential intervention before symptom onset [68].
hnRNP A1 protein levels in cerebrospinal fluid (CSF) and blood are being investigated as potential biomarkers for neurodegenerative diseases [69]. Changes in hnRNP A1 post-translational modifications or aggregation state may reflect disease progression and treatment response [70].
Understanding the molecular mechanisms by which hnRNP A1 mutations cause disease has identified potential therapeutic targets [71]. Strategies aimed at preventing protein aggregation, restoring normal RNA metabolism, or enhancing cellular proteostasis are being explored [72].
Continued research on hnRNP A1 promises to yield further insights into neurodegeneration mechanisms and potential treatments:
Patient-derived iPSC models of neurons carrying HNRNPA1 mutations provide valuable tools for studying disease mechanisms and testing therapeutic interventions [73]. These models enable the examination of cell-autonomous and non-cell-autonomous mechanisms of neurodegeneration [74].
The study of liquid-liquid phase separation in neurodegeneration is rapidly evolving, and hnRNP A1 serves as a key model protein for understanding how membraneless organelle dynamics relate to disease [75]. This research may lead to novel therapeutic strategies targeting phase separation properties [76].
The study of Hnrnpa1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
The two RNA recognition motifs (RRMs) in hnRNP A1 adopt the classic βαββαβ fold:
HnRNP A1 regulates alternative splicing through binding to specific sequences in pre-mRNA:
| Element Type | Location | Effect |
|-------------|----------|--------|
| Exonic splicing silencer (ESS) | Exon | Represses splice site |
| Intronic splicing silencer (ISS) | Intron | Blocks splice site |
| Exonic splicing enhancer (ESE) | Exon | Activates splice site |
The C-terminal prion-related domain (PRD) drives liquid-liquid phase separation (LLPS):
The pathogenic mechanisms in ALS/FTD involve:
TDP-43 and hnRNP A1 frequently co-aggregate in ALS/FTD:
| Feature | TDP-43 | hnRNP A1 |
|---------|--------|----------|
| Primary structure | N-terminal domain, RRM1, RRM2, LCD | N-terminal Gly-rich, RRM1, RRM2, PRD |
| Normal function | RNA/DNA binding, splicing | RNA splicing, transport |
| Disease state | Cytoplasmic aggregates | Cytoplasmic aggregates |
| Common pathology | 95% of ALS cases | ~30% of ALS/FTD cases |
Current therapeutic approaches include:
| Strategy | Target | Status |
|----------|--------|--------|
| ASO therapy | HNRNPA1 mRNA | Preclinical |
| CRISPR editing | Correct mutations | Research |
| Viral delivery | Wild-type HNRNPA1 | Research |
The following diagram shows the key molecular relationships involving HNRNPA1 Protein discovered through SciDEX knowledge graph analysis: